Athenex (ATNX) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Athenex (NASDAQ:ATNX) in a research report report published on Tuesday, The Fly reports.

A number of other brokerages also recently commented on ATNX. BidaskClub downgraded shares of Athenex from a hold rating to a sell rating in a research report on Saturday, December 8th. JPMorgan Chase & Co. raised shares of Athenex from a neutral rating to an overweight rating and dropped their price objective for the company from $24.00 to $15.00 in a research report on Thursday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $20.00.

Shares of ATNX opened at $11.39 on Tuesday. Athenex has a fifty-two week low of $9.83 and a fifty-two week high of $20.90. The company has a market cap of $792.89 million, a P/E ratio of -7.91 and a beta of 0.23. The company has a current ratio of 3.31, a quick ratio of 3.86 and a debt-to-equity ratio of 0.36.

Athenex (NASDAQ:ATNX) last announced its earnings results on Monday, March 11th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.21). Athenex had a negative return on equity of 66.23% and a negative net margin of 131.81%. The business had revenue of $21.27 million for the quarter. On average, research analysts forecast that Athenex will post -1.55 earnings per share for the current fiscal year.

In other news, CEO Johnson Yiu Nam Lau acquired 10,000 shares of the company’s stock in a transaction on Monday, March 11th. The shares were bought at an average cost of $11.78 per share, with a total value of $117,800.00. Following the transaction, the chief executive officer now owns 2,917,422 shares in the company, valued at approximately $34,367,231.16. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Song-Yi Zhang sold 32,240 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.85, for a total transaction of $382,044.00. Following the completion of the sale, the director now directly owns 4,000 shares in the company, valued at $47,400. The disclosure for this sale can be found here. Corporate insiders own 29.50% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Athenex by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 489,666 shares of the company’s stock valued at $6,213,000 after purchasing an additional 35,061 shares during the last quarter. Diag Capital Management LP purchased a new position in shares of Athenex in the 4th quarter valued at $5,445,000. Metropolitan Life Insurance Co. NY grew its position in shares of Athenex by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,245 shares of the company’s stock valued at $181,000 after buying an additional 11,125 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Athenex by 2.2% in the 4th quarter. Squarepoint Ops LLC now owns 69,720 shares of the company’s stock valued at $885,000 after buying an additional 1,494 shares during the last quarter. Finally, Perceptive Advisors LLC grew its position in shares of Athenex by 77.6% in the 4th quarter. Perceptive Advisors LLC now owns 5,096,022 shares of the company’s stock valued at $32,550,000 after buying an additional 2,226,494 shares during the last quarter. 31.81% of the stock is currently owned by institutional investors.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Featured Article: Asset Allocation

The Fly

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.